Provectus Pharmaceuticals Inc. Appoints Kelly M. McMasters, MD, PhD, to Board of Directors

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTC BB: PVCT), a development-stage oncology and dermatology biopharmaceutical company has announced that Kelly M. McMasters MD, PhD, a preeminent authority on melanoma, has agreed to serve as a member of the corporate Board of Directors. Additionally, Dr. McMasters will head the scientific advisory board.

Back to news